Suh Sang-Yeon, Ahn Hong-Yup
Department of Family Medicine, Dongguk University International Hospital, 814 Siksa-dong, Ilsan-dong-gu, Koyang-si, Gyeonggi-do, South Korea.
Eur J Cancer. 2007 Apr;43(6):1051-9. doi: 10.1016/j.ejca.2007.01.031. Epub 2007 Mar 8.
This study evaluated lactate dehydrogenase (LDH) as a prognostic factor for survival time in terminal cancer patients. We prospectively followed 93 consecutive inpatients with terminal cancer in one general hospital. Cox's proportional hazard model was used to adjust the influence of some clinical and laboratory variables on survival time. For 25 patients, LDH levels at 2 weeks and 1 week before death were compared by paired t test. In multivariate analysis, elevated LDH level (313 IU/L) was confirmed as an unfavourable indicator for survival time (hazard ratio=2.087, p=0.002). Serum LDH levels were significantly increased as the patients approached death. A combined index comprising LDH levels, C reactive protein levels, uric acid levels, presence of moderate to severe pain, fatigue, hypotension and performance status demonstrated a good stratification value for predicting survival time. Our results showed that serum LDH level can be a useful predictor of survival time of terminally ill cancer patients.
本研究评估了乳酸脱氢酶（LDH）作为晚期癌症患者生存时间的预后因素。我们前瞻性地跟踪了一家综合医院连续93例晚期癌症住院患者。采用Cox比例风险模型来调整一些临床和实验室变量对生存时间的影响。对25例患者，通过配对t检验比较了死亡前2周和1周时的LDH水平。在多变量分析中，LDH水平升高（313 IU/L）被确认为生存时间的不良指标（风险比=2.087，p=0.002）。随着患者临近死亡，血清LDH水平显著升高。由LDH水平、C反应蛋白水平、尿酸水平、中重度疼痛的存在、疲劳、低血压和体能状态组成的综合指数在预测生存时间方面显示出良好的分层价值。我们的结果表明，血清LDH水平可以作为晚期癌症患者生存时间的有用预测指标。
